Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 7/20 | 0.48 |
| ▸ | F12 | P00748 | 2/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28379911 | 0.85 | TSHR (0.38) | LMNAMAPTNPSR1 | |
| SCHEMBL20577339 | 0.82 | C5AR1 (0.64) | C5AR1F12ESR2MAPTNR1H2 | |
| SCHEMBL20577597 | 0.81 | C5AR1 (0.47) | C5AR1F12ESR2MAPTNR1H2 | |
| SCHEMBL21446959 | 0.78 | C5AR1 (0.60) | C5AR1F12ESR2MAPTNR1H2 | |
| SCHEMBL16379831 | 0.76 | C5AR1 (0.43) | C5AR1F12MKNK1ESR2MAPT | |
| SCHEMBL31163741 | 0.76 | C5AR1 (0.43) | C5AR1F12MKNK1ESR2MAPT | |
| SCHEMBL17327926 | 0.75 | C5AR1 (0.43) | C5AR1F12MKNK1ESR2MAPT | |
| SCHEMBL31345653 | 0.74 | C5AR1 (0.70) | C5AR1 | |
| SCHEMBL20577486 | 0.74 | C5AR1 (0.70) | C5AR1 | |
| SCHEMBL21183650 | 0.73 | F12 (0.52) | C5AR1F12MKNK1ESR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773091-B2 | 6-5 fused rings as C5a inhibitors | CHEMOCENTRYX, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20230151002-A1 | 6-5 FUSED RINGS AS C5a INHIBITORS | CHEMOCENTRYX, INC. | 2023-05-18 | — | — | US | disclosed |
| EP-3630775-B1 | 6-5 FUSED RINGS AS C5a INHIBITORS | CHEMOCENTRYX INC (US) | 2022-12-14 | — | — | EP | disclosed |
| US-11384079-B2 | 6-5 fused rings as C5a inhibitors | CHEMOCENTRYX, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20200347049-A1 | 6-5 FUSED RINGS AS C5a INHIBITORS | CHEMOCENTRYX, INC. | 2020-11-05 | — | — | US | disclosed |
| EP-3630775-A1 | 6-5 FUSED RINGS AS C5a INHIBITORS | ChemoCentryx, Inc. (US) | 2020-04-08 | — | — | EP | disclosed |
| US-10562896-B2 | 6-5 fused rings as C5a inhibitors | CHEMOCENTRYX, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20180370967-A1 | 6-5 FUSED RINGS AS C5a INHIBITORS | CHEMOCENTRYX, INC. | 2018-12-27 | — | — | US | disclosed |
| WO-2018222598-A1 | 6-5 FUSED RINGS AS C5a INHIBITORS | CHEMOCENTRYX, INC. (US) | 2018-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347049-A1 | 6-5 FUSED RINGS AS C5a INHIBITORS | C5AR1, C5AR2, C3AR1 | C5AR1 1/4885F12 27/4885MKNK1 3893/4885 |
| US-20230151002-A1 | 6-5 FUSED RINGS AS C5a INHIBITORS | C5AR1, C5AR2, C3AR1 | C5AR1 1/4885F12 27/4885MKNK1 3893/4885 |
| US-11773091-B2 | 6-5 fused rings as C5a inhibitors | C5AR1, C5AR2, C3AR1 | C5AR1 1/4885F12 27/4885MKNK1 3893/4885 |
| US-11384079-B2 | 6-5 fused rings as C5a inhibitors | C5AR1, C5AR2, C3AR1 | C5AR1 1/4885F12 27/4885MKNK1 3893/4885 |
| US-10562896-B2 | 6-5 fused rings as C5a inhibitors | C5AR1, C5AR2, C3AR1 | C5AR1 1/4885F12 27/4885MKNK1 3893/4885 |
| US-20180370967-A1 | 6-5 FUSED RINGS AS C5a INHIBITORS | C5AR1, C5AR2, C3AR1 | C5AR1 1/4885F12 27/4885MKNK1 3893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.